Lv1
30 积分 2024-12-26 加入
ABCL-366 Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma
1天前
求助中
An Innovative Approach to Optimize First‐In‐Human Minimal Anticipated Biological Effect Level Based Starting Dose in Oncology Trials for Bispecific T‐Cell Engagers: Experience from A Solid Tumor Bispecific T‐Cell Engager
1个月前
已完结
Fifth Generation Cellular Networks for Underground Block Cave Mining: A Position Paper
3个月前
已完结
Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin
4个月前
已关闭
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
5个月前
已完结
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
5个月前
已完结
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
5个月前
已完结
The promise of bispecific antibodies: Clinical applications and challenges
5个月前
已完结
皖公网安备34019202002308
